Vancouver-based Vitaeris is focused on developing a monoclonal antibody called clazakizumab, which targets chronic inflammatory diseases. The company has licensed the rights to this antibody from Alder Biopharmaceuticals and is actively pursuing innovative applications in the field. In June 2020, Vitaeris was acquired by CSL Behring, although the terms of the transaction were not disclosed.